JP2008529539A5 - - Google Patents

Download PDF

Info

Publication number
JP2008529539A5
JP2008529539A5 JP2007555430A JP2007555430A JP2008529539A5 JP 2008529539 A5 JP2008529539 A5 JP 2008529539A5 JP 2007555430 A JP2007555430 A JP 2007555430A JP 2007555430 A JP2007555430 A JP 2007555430A JP 2008529539 A5 JP2008529539 A5 JP 2008529539A5
Authority
JP
Japan
Prior art keywords
composition
amino acid
acid sequence
polypeptide
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007555430A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008529539A (ja
JP5175108B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2005/001158 external-priority patent/WO2006086870A1/en
Publication of JP2008529539A publication Critical patent/JP2008529539A/ja
Publication of JP2008529539A5 publication Critical patent/JP2008529539A5/ja
Application granted granted Critical
Publication of JP5175108B2 publication Critical patent/JP5175108B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007555430A 2005-02-18 2005-07-21 血液脳関門を介して化合物を輸送するためのアプロチニンポリペプチド Expired - Fee Related JP5175108B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65392805P 2005-02-18 2005-02-18
US60/653,928 2005-02-18
PCT/CA2005/001158 WO2006086870A1 (en) 2005-02-18 2005-07-21 Aprotinin polypeptides for transporting a compound across the blood-brain barrier

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011004842A Division JP5462193B2 (ja) 2005-02-18 2011-01-13 血液脳関門を介して化合物を輸送するためのアプロチニンポリペプチド

Publications (3)

Publication Number Publication Date
JP2008529539A JP2008529539A (ja) 2008-08-07
JP2008529539A5 true JP2008529539A5 (enExample) 2008-09-18
JP5175108B2 JP5175108B2 (ja) 2013-04-03

Family

ID=36916132

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007555430A Expired - Fee Related JP5175108B2 (ja) 2005-02-18 2005-07-21 血液脳関門を介して化合物を輸送するためのアプロチニンポリペプチド
JP2011004842A Expired - Fee Related JP5462193B2 (ja) 2005-02-18 2011-01-13 血液脳関門を介して化合物を輸送するためのアプロチニンポリペプチド
JP2013245690A Pending JP2014088386A (ja) 2005-02-18 2013-11-28 血液脳関門を介して化合物を輸送するためのアプロチニンポリペプチド

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011004842A Expired - Fee Related JP5462193B2 (ja) 2005-02-18 2011-01-13 血液脳関門を介して化合物を輸送するためのアプロチニンポリペプチド
JP2013245690A Pending JP2014088386A (ja) 2005-02-18 2013-11-28 血液脳関門を介して化合物を輸送するためのアプロチニンポリペプチド

Country Status (18)

Country Link
US (4) US7902156B2 (enExample)
EP (2) EP2360258B1 (enExample)
JP (3) JP5175108B2 (enExample)
CN (2) CN101160403B (enExample)
AT (1) ATE551422T1 (enExample)
AU (1) AU2005327497B2 (enExample)
BR (1) BRPI0520032A2 (enExample)
CA (1) CA2597958C (enExample)
CY (1) CY1113299T1 (enExample)
DK (2) DK1859041T4 (enExample)
ES (2) ES2527634T3 (enExample)
MX (1) MX2007010113A (enExample)
PL (2) PL1859041T5 (enExample)
PT (2) PT1859041E (enExample)
RU (2) RU2408605C2 (enExample)
SI (2) SI2360258T1 (enExample)
WO (1) WO2006086870A1 (enExample)
ZA (1) ZA200706917B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2368941T3 (es) * 2003-01-06 2011-11-23 Angiochem Inc. Angiopep-1, compuestos relacionados y utilizaciones correspondientes.
US7485706B2 (en) * 2003-07-30 2009-02-03 The Board Of Trustees Of The Leland Stanford Junior University Neurodegenerative protein aggregation inhibition methods and compounds
CA2589860A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
RU2408605C2 (ru) 2005-02-18 2011-01-10 Анджиокем Инк. Полипептид, способный преодолевать гематоэнцефалический барьер, и его конъюгат
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
PL2233156T3 (pl) * 2005-07-15 2013-09-30 Angiochem Inc Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych
EP2074142A4 (en) * 2006-10-19 2010-10-27 Angiochem Inc COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
JP5844971B2 (ja) * 2007-05-29 2016-01-20 アンジオケム，インコーポレーテッド コンジュゲートされた物質を組織に送達するためのアプロチニン様ポリペプチド
CN101815724B (zh) * 2007-05-29 2015-02-25 安吉奥开米公司 用于将轭合至其的试剂递送至组织的抑肽酶样多肽
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
CA2709635A1 (en) * 2007-12-20 2009-07-02 Angiochem Inc. Polypeptide-nucleic acid conjugates and uses thereof
EP2261254A3 (en) 2007-12-21 2011-04-13 Amgen, Inc Anti-amyloid antibodies and uses thereof
CA2721169A1 (en) * 2008-04-14 2009-10-22 Proscan Rx Pharma Inc. Prostate specific membrane antigen antibodies and antigen binding fragments
JP5860698B2 (ja) * 2008-04-18 2016-02-16 アンジオケム，インコーポレーテッド パクリタキセル、パクリタキセル類似体またはパクリタキセルコンジュゲートの医薬組成物ならびに関連する調製方法および使用方法
JP5705118B2 (ja) * 2008-10-15 2015-04-22 アンジオケム インコーポレーテッド 薬物送達のためのエトポシドおよびドキソルビシン複合体
EP2346906A4 (en) * 2008-10-15 2013-04-24 Angiochem Inc CONJUGATES FROM GLP-1 AGONISTS AND THEIR USE
BRPI0923283A2 (pt) * 2008-12-05 2017-06-06 Angiochem Inc conjugados terapêuticos de peptídeo e usos dos mesmos
US20110288009A1 (en) * 2008-12-05 2011-11-24 Angiochem Inc. Leptin and leptin analog conjugates and uses thereof
JP5759379B2 (ja) * 2008-12-05 2015-08-05 アンジオケム インコーポレーテッド ニューロテンシンまたはニューロテンシンアナログおよびその使用
WO2010069074A1 (en) 2008-12-17 2010-06-24 Universite Du Quebec A Montreal Membrane type-1 matrix metalloprotein inhibitors and uses thereof
EP2421562B1 (en) * 2009-04-20 2019-03-13 Angiochem Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US20100284921A1 (en) * 2009-05-08 2010-11-11 Temple University - Of The Commonwealth System Of Higher Education Targeted nanoparticles for intracellular cancer therapy
US20120196803A1 (en) * 2009-06-11 2012-08-02 Angiochem Inc. Fusion proteins for delivery of gdnf and bdnf to the central nervous system
RU2012103240A (ru) * 2009-07-02 2013-08-10 Ангиокем Инк. Мультимерные пептидные конъюгаты и их применение
US20120277158A1 (en) * 2009-10-06 2012-11-01 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
KR101806323B1 (ko) 2009-11-13 2017-12-07 다이이치 산쿄 유럽 게엠베하 Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법
RU2013103763A (ru) 2010-07-02 2014-08-10 Ангиохем Инк. Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения
US20130280281A1 (en) * 2010-07-02 2013-10-24 Jean-Paul Castaigne Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
JP2013540694A (ja) 2010-08-06 2013-11-07 ウー３・フアルマ・ゲー・エム・ベー・ハー Ｈｅｒ３結合剤の前立腺治療における使用
CN102614524A (zh) * 2011-02-01 2012-08-01 复旦大学 低密度脂蛋白受体相关蛋白配体多肽修饰的脑肿瘤靶向基因递释复合物
WO2013056096A1 (en) * 2011-10-13 2013-04-18 Angiochem Inc. Polypeptide-opioid conjugates and uses thereof
EP2885318A4 (en) 2012-08-14 2016-03-30 Angiochem Inc PEPTIDE DENDRIMER CONJUGATES AND ITS USES
JP6108265B2 (ja) * 2012-11-19 2017-04-05 国立大学法人 千葉大学 脳送達用キャリアおよびその用途
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
MX367600B (es) * 2014-02-19 2019-08-28 Hoffmann La Roche Transportador de la barrera hematoencefálica.
US11318206B2 (en) 2014-03-28 2022-05-03 Aposense Ltd Compounds and methods for trans-membrane delivery of molecules
US9993563B2 (en) * 2014-03-28 2018-06-12 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
JP6669719B2 (ja) * 2014-03-28 2020-03-18 アポセンス リミテッドＡｐｏｓｅｎｓｅ Ｌｔｄ． 分子の膜貫通送達のための化合物および方法
US9655998B2 (en) 2014-08-07 2017-05-23 Cook Medical Technologies Llc Encapsulated drug compositions and methods of use thereof
US11241520B2 (en) 2014-08-07 2022-02-08 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US9180226B1 (en) 2014-08-07 2015-11-10 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
EP3795580A1 (en) 2014-10-03 2021-03-24 University of Massachusetts High efficiency library-identified aav vectors
WO2016054554A1 (en) 2014-10-03 2016-04-07 University Of Massachusetts Heterologous targeting peptide grafted aavs
US10258699B2 (en) 2014-10-24 2019-04-16 University Of Science And Technology Of China Angiopep and derivatives thereof for imaging amyloids
EA037271B1 (ru) * 2014-11-06 2021-03-02 Озе Иммьюнотерапьютикс Мультипептидный т-специфичный иммунотерапевтический препарат для лечения метастазов рака в головном мозге
US10584321B2 (en) 2015-02-13 2020-03-10 University Of Massachusetts Compositions and methods for transient delivery of nucleases
JP6612063B2 (ja) * 2015-06-11 2019-11-27 国立大学法人滋賀医科大学 悪性神経膠腫分子標的ペプチド
CA2989400A1 (en) * 2015-06-15 2016-12-22 Angiochem Inc. Ang1005 for the treatment of leptomeningeal carcinomatosis
PL417159A1 (pl) 2016-05-11 2017-11-20 Instytut Biologii Doświadczalnej Im. Marcelego Nenckiego Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby Alzheimera
US20180009869A1 (en) * 2016-07-08 2018-01-11 AskGene Pharma, Inc. Fusion Protein Comprising Leptin and Methods for Producing and Using the Same
US10702589B2 (en) 2016-10-04 2020-07-07 Ann And Robert H. Lurie Children's Hospital Of Chicago Compositions and methods of treating neurological disorder and stress-induced conditions
AU2018205898B2 (en) 2017-01-09 2020-12-10 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
JP7820060B2 (ja) 2018-01-01 2026-02-25 アポセンス リミテッド 分子の膜貫通送達のための化合物および方法
US10688191B2 (en) 2018-01-19 2020-06-23 Hr Biomed, Llc Delivery of a chemotherapy agent across the blood-brain barrier
CN109666973B (zh) * 2018-11-21 2022-11-04 北京大学 一种穿过血脑屏障的肽库及其筛选方法
WO2021188802A1 (en) * 2020-03-18 2021-09-23 Brown Kathlynn C Molecular transport system to the central nervous system
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier
WO2022156531A1 (zh) * 2021-01-19 2022-07-28 中国人民解放军军事科学院军事医学研究院 一种能够透过生物屏障的动力蛋白结合肽及其应用
CN112851789B (zh) * 2021-02-04 2022-10-18 大理大学 一种脑靶向hiv进入抑制剂多肽及其应用
MX2023009768A (es) * 2021-02-22 2024-01-17 Univ Yale Degradadores bifuncionales dirigidos y métodos de uso de los mismos.

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
WO1987005702A1 (en) 1986-03-13 1987-09-24 Biotechnology Australia Pty. Ltd. Method of assay of inhibin
GB2188322A (en) * 1986-03-26 1987-09-30 Bayer Ag Aprotinin and analogues thereof produced by a recombinant host
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4904768A (en) 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
GB2208511A (en) * 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5632990A (en) 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
US5258499A (en) 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US5028697A (en) 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5169933A (en) 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
DE3912638A1 (de) * 1989-04-18 1990-10-31 Bayer Ag Gentechnologisch hergestellte homologe des alzheimer protease inhibitors, wirtstaemme sowie expressionsvektoren fuer ihre herstellung und ihre verwendung als arzneimittel
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US6475781B1 (en) 1990-05-17 2002-11-05 Dana-Farber Cancer Institute, Inc. Trans-dominant suppressor genes for oligomeric proteins
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US6495513B1 (en) 1991-03-11 2002-12-17 Curis, Inc. Morphogen-enhanced survival and repair of neural cells
US5955444A (en) 1991-08-09 1999-09-21 Massachusetts Institute Of Technology Method of inhibiting abnormal tau hyper phosphorylation in a cell
US5627270A (en) 1991-12-13 1997-05-06 Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
WO1994007528A1 (en) 1992-09-25 1994-04-14 Corvas International, Inc. Bovine pancreatic trypsin inhibitor derived inhibitors of factor viia-tissue factor complex
WO1994019692A1 (en) 1993-02-18 1994-09-01 The General Hospital Corporation Alzheimer's disease therapeutics
WO1996031531A2 (en) 1995-04-04 1996-10-10 Advanced Bioconcept, Inc. Fluorescent peptides
ZA963619B (en) * 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
WO1996035788A2 (en) * 1995-05-08 1996-11-14 Scios, Inc. Kunitz type protease inhibitors
WO1996039183A1 (en) 1995-05-31 1996-12-12 Fred Hutchinson Cancer Research Center Compositions and methods for targeted delivery of effector molecules
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
AU716923B2 (en) * 1996-03-11 2000-03-09 Aerovance, Inc. Human bikunin
WO1997040854A2 (en) 1996-05-01 1997-11-06 Antivirals Inc. Polypeptide conjugates for transporting substances across cell membranes
DE19629982A1 (de) * 1996-07-25 1998-01-29 Bayer Ag Aprotinin-Varianten mit verbesserten Eigenschaften
JP2001503396A (ja) 1996-10-11 2001-03-13 アルザ コーポレイション 治療用リポソーム組成物および方法
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
IL131655A0 (en) 1997-03-04 2001-01-28 Bio Technology General Corp Isolation of tissue specific ligands and their use for targeting pharmaceuticals to organs
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
IL132941A0 (en) 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US6475481B2 (en) * 1997-11-18 2002-11-05 Canji Inc Purging of stem cell products
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US5981564A (en) 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US5922754A (en) 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
US6191290B1 (en) 1999-02-24 2001-02-20 Uab Research Foundation Taxane derivatives for targeted therapy of cancer
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
US6180607B1 (en) * 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
DE19953696A1 (de) 1999-11-09 2001-05-10 Alexander Cherkasky Selektive proteolytische Synzyme (SPS)
CA2355334A1 (en) 2000-10-16 2002-04-16 Procyon Biopharma Inc. Pharmaceutical preparations and methods for inhibiting tumors
WO2002076448A1 (en) 2001-03-23 2002-10-03 Napro Biotherapeutics, Inc. Molecular conjugates for use in treatment of cancer
EP2147679B1 (en) 2001-07-25 2014-06-25 Raptor Pharmaceutical, Inc. Compositions for blood-brain barrier transport
CN1195845C (zh) * 2001-10-08 2005-04-06 中国医学科学院阜外心血管病医院 人源抑肽酶基因、该基因编码的蛋白质及其应用
US7192921B2 (en) 2001-11-08 2007-03-20 The Burnham Institute Peptides that home to tumor lymphatic vasculature and methods of using same
ATE365213T1 (de) 2002-02-07 2007-07-15 Yissum Res Dev Co Aminosäuresequenzen die die fähigkeit besitzen, die durchdringung durch eine biologische barriere erleichtern
US20050215478A1 (en) * 2002-02-07 2005-09-29 Ben-Sasson Shmuel A Amino acid sequences capable of facilitating penetration across a biological barrier
WO2004003145A2 (en) 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
ES2368941T3 (es) 2003-01-06 2011-11-23 Angiochem Inc. Angiopep-1, compuestos relacionados y utilizaciones correspondientes.
AU2003286870A1 (en) * 2003-06-05 2005-01-04 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
WO2005002515A2 (en) 2003-06-20 2005-01-13 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7927811B2 (en) 2003-08-08 2011-04-19 Proteus Sciences Co., Ltd. Polypeptides having brain-localizing activity and uses thereof
US20050058702A1 (en) 2003-09-17 2005-03-17 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US7208174B2 (en) 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
CA2580189C (en) 2004-09-29 2013-05-21 Children's Memorial Hospital Sirna-mediated gene silencing of alpha synuclein
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
RU2408605C2 (ru) * 2005-02-18 2011-01-10 Анджиокем Инк. Полипептид, способный преодолевать гематоэнцефалический барьер, и его конъюгат
CA2616906A1 (en) 2005-05-12 2006-11-23 Tapestry Pharmaceuticals, Inc. Molecular constructs suitable for targeted conjugates
PL2233156T3 (pl) 2005-07-15 2013-09-30 Angiochem Inc Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych
GB0517092D0 (en) 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
EP1934359A2 (en) 2005-09-08 2008-06-25 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions for delivery of ribonucleic acid to a cell
CA2627585A1 (en) 2005-11-01 2007-05-10 Alnylam Pharmaceuticals, Inc. Rnai inhibition of influenza virus replication
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
ATE524493T1 (de) 2006-07-24 2011-09-15 Biorexis Pharmaceutical Corp Exendin-fusionsproteine
EP2074142A4 (en) 2006-10-19 2010-10-27 Angiochem Inc COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
CN101815724B (zh) 2007-05-29 2015-02-25 安吉奥开米公司 用于将轭合至其的试剂递送至组织的抑肽酶样多肽
US8802631B2 (en) 2007-09-17 2014-08-12 Ludwig Institute For Cancer Research Ltd. Peptides and methods for the treatment of gliomas and other cancers
WO2009070597A2 (en) 2007-11-26 2009-06-04 Armagen Technologies, Inc. Fusion proteins for delivery of gdnf to the cns
CA2709635A1 (en) 2007-12-20 2009-07-02 Angiochem Inc. Polypeptide-nucleic acid conjugates and uses thereof
JP5860698B2 (ja) 2008-04-18 2016-02-16 アンジオケム，インコーポレーテッド パクリタキセル、パクリタキセル類似体またはパクリタキセルコンジュゲートの医薬組成物ならびに関連する調製方法および使用方法
JP5705118B2 (ja) 2008-10-15 2015-04-22 アンジオケム インコーポレーテッド 薬物送達のためのエトポシドおよびドキソルビシン複合体
EP2346906A4 (en) 2008-10-15 2013-04-24 Angiochem Inc CONJUGATES FROM GLP-1 AGONISTS AND THEIR USE
JP5759379B2 (ja) 2008-12-05 2015-08-05 アンジオケム インコーポレーテッド ニューロテンシンまたはニューロテンシンアナログおよびその使用
US20110288009A1 (en) 2008-12-05 2011-11-24 Angiochem Inc. Leptin and leptin analog conjugates and uses thereof
BRPI0923283A2 (pt) 2008-12-05 2017-06-06 Angiochem Inc conjugados terapêuticos de peptídeo e usos dos mesmos
WO2010069074A1 (en) 2008-12-17 2010-06-24 Universite Du Quebec A Montreal Membrane type-1 matrix metalloprotein inhibitors and uses thereof

Similar Documents

Publication Publication Date Title
JP2008529539A5 (enExample)
Park Protein–nanoparticle interaction: corona formation and conformational changes in proteins on nanoparticles
RU2007134566A (ru) Полипептиды апротинина для транспорта соединения через гематоэнцефалический барьер
Ribovski et al. Polymeric nanoparticles properties and brain delivery
JP2009500431A5 (enExample)
RU2010129761A (ru) Конъюгаты полипептидов с нуклеиновыми кислотами и их применение
Zhang et al. Nanomaterials for reducing amyloid cytotoxicity
JP2010524849A5 (enExample)
Liu et al. D‐peptides as recognition molecules and therapeutic agents
CA2516056A1 (en) Aprotinin and analogs as carriers across the blood-brain barrier
Ye et al. 15 years of ATTEMPTS: A macromolecular drug delivery system based on the CPP-mediated intracellular drug delivery and antibody targeting
JP2011505846A5 (enExample)
JP2010514839A5 (enExample)
JP2009502135A5 (enExample)
JP2020505326A (ja) Ｔｅａｄ相互作用を妨害するためのペプチド組成物およびその使用方法
JP2015509097A5 (enExample)
RU2008105677A (ru) Усиление действия противораковых агентов
JP2011518179A5 (enExample)
Capule et al. Oligovalent amyloid-binding agents reduce SEVI-mediated enhancement of HIV-1 infection
JP2013506411A5 (enExample)
JP2019501141A5 (enExample)
JP2016509586A5 (enExample)
JP2019535267A5 (enExample)
UA102061C2 (ru) Агонистическое антитело к notch3 и его применение для лечения notch3- ассоциированных заболеваний
Zhang et al. Brain targeting and Aβ binding bifunctional nanoparticles inhibit amyloid protein aggregation in APP/PS1 transgenic mice